A Study to Investigate the Safety, Tolerability, and Preliminary Efficacy With AION-301 Administered by Intravenous Infusion Compared With Placebo Administered by Intravenous Infusion Investigational Intervention in Participants Aged 35 to 75 Years of Age With Chronic Kidney Disease (CKD)
NCT06721143
This study is recruiting at 2 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this clinical trial is to learn about the safety (good or bad) of giving two AION-301 intravenous (IV) infusions, in adults with Stage 3 Chronic Kidney Disease (CKD). It will also help to learn if AION-301 reduces the symptoms of CKD and/or progression. The main questions it aims to answer are: Do participants have medical problems (adverse events) after receiving two infusions of AION-301? Do participants feel better (have reduced and/or delayed CKD symptoms)? To learn about how AION-301 works in participants with CKD?
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Chronic Kidney Disease Stage 3
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 35 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- AION Healthspan, Inc.
- Last updated on ClinicalTrials.gov
- April 1, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 2
- SouthCoast Research Center, Inc. · Miami, FL
- University of Miami, Leonard M. Miller School of Medicine · Miami, FL
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.